Details of the Drug Reposition

General Information of This Drug (ID: DMI9PRJ)

• Drug Name: Diflorasone (DMI9PRJ)
• Synonyms: Diflorasona; Diflorasonum; Maxiflor; Murode; U 34865; Diflorasona [INN-Spanish]; Diflorasone (INN); Diflorasone [INN:BAN]; Diflorasonum [INN-Latin]; Murode (TN); (6S,8S,9R,10S,11S,13S,14S,16S,17R)-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (6alpha,11beta,16beta)-6,9-difluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 6a,9a-difluoro-16b-methylprednisolone; 6alpha,9-Difluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione
• Therapeutic Class: Antiinflammatory Agents
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

4 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Primary cutaneous T-cell lymphoma	DIS35WVW	N.A.	Approved	[1]
Granuloma annulare	DISMOUMI	N.A.	Approved	[1]
Exanthem	DISAFOQN	N.A.	Approved	[1]
Rosacea	DIS02PWG	ED90.0	Approved	[2]

1 Discontinued in Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Contact dermatitis	DISQ3AU0	EK0Z	Discontinued in Phase 2	[3]

2 Discontinued in Phase 1 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Atopic dermatitis	DISTCP41	EA80	Discontinued in Phase 1	[4]
Seborrhoeic dermatitis	DISNWVJU	EA81	Discontinued in Phase 1	[5]

References

• [1] Diflorasone FDA Label
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma
• [4] A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)
• [5] A Trial of Inflammatory Markers, Depressive Symptoms, and Heart Disease